tradingkey.logo

Icecure Medical Ltd

ICCM
0.590USD
+0.039+7.04%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
40.69MMarktkapitalisierung
VerlustKGV TTM

Icecure Medical Ltd

0.590
+0.039+7.04%

mehr Informationen über Icecure Medical Ltd Unternehmen

Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.

Icecure Medical Ltd Informationen

BörsenkürzelICCM
Name des UnternehmensIcecure Medical Ltd
IPO-datumFeb 02, 2011
CEOShamir (Eyal)
Anzahl der mitarbeiter64
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 02
Addresse7 Ha'eshel St.
StadtCAESAREA
BörseNASDAQ OMX - NASDAQ BASIC
LandIsrael
Postleitzahl3079504
Telefon97246230333
Websitehttps://icecure-medical.com/
BörsenkürzelICCM
IPO-datumFeb 02, 2011
CEOShamir (Eyal)

Führungskräfte von Icecure Medical Ltd

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Eyal Shamir
Mr. Eyal Shamir
Chief Executive Officer, Director
Chief Executive Officer, Director
590.31K
+69673.00%
Mr. Ronen Tsimerman
Mr. Ronen Tsimerman
Vice President - Finance, Vice President - Operations
Vice President - Finance, Vice President - Operations
355.08K
+47555.00%
Mr. Naum Muchnik
Mr. Naum Muchnik
Vice President - Research & Development
Vice President - Research & Development
140.42K
+35127.00%
Mr. Oded Tamir
Mr. Oded Tamir
External Director
External Director
20.00K
+10000.00%
Ms. Tlalit Bussi Tel-Tzure
Ms. Tlalit Bussi Tel-Tzure
Vice President - Business Development & Marketing
Vice President - Business Development & Marketing
--
--
Ms. Sharon Levita
Ms. Sharon Levita
External Director
External Director
--
--
Ms. Elisabeth Sadka
Ms. Elisabeth Sadka
Vice President-Clinics, Regulations and Quality Assurance
Vice President-Clinics, Regulations and Quality Assurance
--
--
Mr. Yaacov Goldman
Mr. Yaacov Goldman
External Director
External Director
--
--
Mr. Doron Birger
Mr. Doron Birger
Independent Director
Independent Director
--
--
Mr. Ron Abraham Mayron
Mr. Ron Abraham Mayron
Chairman of the Board
Chairman of the Board
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Eyal Shamir
Mr. Eyal Shamir
Chief Executive Officer, Director
Chief Executive Officer, Director
590.31K
+69673.00%
Mr. Ronen Tsimerman
Mr. Ronen Tsimerman
Vice President - Finance, Vice President - Operations
Vice President - Finance, Vice President - Operations
355.08K
+47555.00%
Mr. Naum Muchnik
Mr. Naum Muchnik
Vice President - Research & Development
Vice President - Research & Development
140.42K
+35127.00%
Mr. Oded Tamir
Mr. Oded Tamir
External Director
External Director
20.00K
+10000.00%
Ms. Tlalit Bussi Tel-Tzure
Ms. Tlalit Bussi Tel-Tzure
Vice President - Business Development & Marketing
Vice President - Business Development & Marketing
--
--
Ms. Sharon Levita
Ms. Sharon Levita
External Director
External Director
--
--

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2024
FY2023
FY2022
FY2021
FY2020
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
Other
1.46M
44.24%
United States
870.00K
26.44%
Japan
481.00K
14.62%
India
413.00K
12.55%
China
41.00K
1.25%
Israel
30.00K
0.91%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Sat, Jan 31
Aktualisiert: Sat, Jan 31
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Haixiang (Li)
37.48%
Shamir (Eyal)
0.86%
Tsimerman (Ronen)
0.51%
Mayron (Ron)
0.40%
Tel-Tzure (Tlalit Bussi)
0.28%
Andere
60.47%
Aktionäre
Aktionäre
Anteil
Haixiang (Li)
37.48%
Shamir (Eyal)
0.86%
Tsimerman (Ronen)
0.51%
Mayron (Ron)
0.40%
Tel-Tzure (Tlalit Bussi)
0.28%
Andere
60.47%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
40.42%
Investment Advisor
0.39%
Hedge Fund
0.13%
Investment Advisor/Hedge Fund
0.06%
Research Firm
0.02%
Bank and Trust
0.02%
Venture Capital
0.02%
Andere
58.94%

Institutionelle Beteiligung

Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
31
443.26K
0.64%
+86.28K
2025Q3
33
241.02K
0.35%
-53.58K
2025Q2
45
28.04M
40.84%
+56.20K
2025Q1
44
28.01M
47.78%
-9.18K
2024Q4
41
27.61M
48.82%
+489.62K
2024Q3
42
27.95M
49.54%
-2.17M
2024Q2
41
27.48M
56.81%
+3.00M
2024Q1
39
27.22M
56.29%
+2.63M
2023Q4
40
21.73M
47.63%
-6.82M
2023Q3
37
21.68M
47.52%
-6.84M
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Haixiang (Li)
25.85M
37.48%
--
--
Dec 31, 2024
Shamir (Eyal)
590.31K
0.86%
+69.67K
+13.38%
Mar 24, 2025
Tsimerman (Ronen)
355.08K
0.51%
+47.55K
+15.46%
Mar 24, 2025
Mayron (Ron)
278.02K
0.4%
+55.45K
+24.91%
Mar 24, 2025
Tel-Tzure (Tlalit Bussi)
191.81K
0.28%
+35.32K
+22.57%
Mar 24, 2025
Levav (Shay)
141.86K
0.21%
+37.69K
+36.18%
Mar 24, 2025
Muchnik (Naum)
140.42K
0.2%
+35.13K
+33.36%
Mar 24, 2025
Huang (Yang)
113.44K
0.16%
+40.12K
+54.72%
Mar 24, 2025
Dotan (Merav Nir)
88.94K
0.13%
+30.84K
+53.09%
Mar 24, 2025
Malik (Galit)
79.67K
0.12%
+23.32K
+41.40%
Mar 24, 2025
Mehr Anzeigen

Verbundene ETFs

Name
Anteil
Keine Daten

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI